Adsorption Procedure Enhances Efficiency of Drug Transport
By LabMedica International staff writers Posted on 31 Jul 2018 |
Image: Combining a nanocarrier with antibodies under acidic conditions results in the antibodies attaching to the drug carrier in a stable way. This makes it possible for nanocarriers to target diseased tissue (Photo courtesy of Stefan Schuhmacher).
A simple adsorption procedure enhances the efficiency of nanocarrier transport of toxic drugs to tumors.
To promote drug delivery to exact sites and cell types, the surface of nanocarriers is functionalized with targeting antibodies or ligands, typically coupled by covalent chemistry. Once the nanocarrier is exposed to biological fluid such as plasma, however, its surface is inevitably covered with various biomolecules forming a protein corona, which masks the targeting ability of the nanoparticle.
To get around the protein-masking problem, investigators at Johannes Gutenberg University Mainz (Germany) developed a pre-adsorption process to attach targeting antibodies to the surface of the nanocarrier.
The investigators reported in the June 18, 2018, online edition of the journal Nature Nanotechnology that pre-adsorbed antibodies remained functional and were not completely exchanged or covered by the biomolecular corona, whereas coupled antibodies were more affected by this shielding.
"Up to now, we have always had to use elaborate chemical methods to bind these antibodies to nanocapsules," said senior author Dr. Volker Mailänder, head of the nanocarriers for medical applications group at the Johannes Gutenberg University Mainz. "We have now been able to show that all that you need to do is to combine antibodies and nanocapsules together in an acidified solution."
Related Links:
Johannes Gutenberg University Mainz
To promote drug delivery to exact sites and cell types, the surface of nanocarriers is functionalized with targeting antibodies or ligands, typically coupled by covalent chemistry. Once the nanocarrier is exposed to biological fluid such as plasma, however, its surface is inevitably covered with various biomolecules forming a protein corona, which masks the targeting ability of the nanoparticle.
To get around the protein-masking problem, investigators at Johannes Gutenberg University Mainz (Germany) developed a pre-adsorption process to attach targeting antibodies to the surface of the nanocarrier.
The investigators reported in the June 18, 2018, online edition of the journal Nature Nanotechnology that pre-adsorbed antibodies remained functional and were not completely exchanged or covered by the biomolecular corona, whereas coupled antibodies were more affected by this shielding.
"Up to now, we have always had to use elaborate chemical methods to bind these antibodies to nanocapsules," said senior author Dr. Volker Mailänder, head of the nanocarriers for medical applications group at the Johannes Gutenberg University Mainz. "We have now been able to show that all that you need to do is to combine antibodies and nanocapsules together in an acidified solution."
Related Links:
Johannes Gutenberg University Mainz
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples